<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Kazan medical journal</journal-id><journal-title-group><journal-title xml:lang="en">Kazan medical journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Казанский медицинский журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0368-4814</issn><issn publication-format="electronic">2587-9359</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">64594</article-id><article-id pub-id-type="doi">10.17816/kazmj64594</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Prospects for immunomodulatory therapy of bronchial asthma</article-title><trans-title-group xml:lang="ru"><trans-title>Перспективы иммуномодулирующей терапии бронхиальной астмы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Cherepnev</surname><given-names>G. V.</given-names></name><name xml:lang="ru"><surname>Черепнев</surname><given-names>Г. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Doctor of Medical Sciences, Head of the Scientific Department, Department of Clinical Pharmacology and Pharmacotherapy</p> <p> </p><p> </p> </bio><bio xml:lang="ru"><p>Доктор медицинских наук, заведующий научным отделом, Кафедра клинической фармакологии и фармакотерапии</p></bio><email>info@eco-vector.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Slabnov</surname><given-names>Y. D.</given-names></name><name xml:lang="ru"><surname>Слабнов</surname><given-names>Ю. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Scientific Department, Department of Clinical Pharmacology and Pharmacotherapy</p></bio><bio xml:lang="ru"><p>Научный отдел, Кафедра клинической фармакологии и фармакотерапии</p></bio><email>info@eco-vector.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zimakova</surname><given-names>I. E.</given-names></name><name xml:lang="ru"><surname>Зимакова</surname><given-names>И. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Professor, Head of the Department of Clinical Pharmacology and Pharmacotherapy, Scientific Department</p> <p> </p><p> </p> </bio><bio xml:lang="ru"><p>Профессор, заведующий кафедрой клинической фармакологии и фармакотерапии, Научный отдел</p></bio><email>info@eco-vector.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Republican Medical Diagnostic Center</institution></aff><aff><institution xml:lang="ru">Республиканский медицинский диагностический центр</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Kazan State Medical Academy of Postgraduate Education</institution></aff><aff><institution xml:lang="ru">Казанская государственная медицинская академия последипломного образования</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="1998-09-14" publication-format="electronic"><day>14</day><month>09</month><year>1998</year></pub-date><volume>79</volume><issue>5</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>388</fpage><lpage>391</lpage><history><date date-type="received" iso-8601-date="2021-04-03"><day>03</day><month>04</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-04-03"><day>03</day><month>04</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 1998, Cherepnev G.V., Slabnov Y.D., Zimakova I.E.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 1998, Черепнев Г.В., Слабнов Ю.Д., Зимакова И.Е.</copyright-statement><copyright-year>1998</copyright-year><copyright-holder xml:lang="en">Cherepnev G.V., Slabnov Y.D., Zimakova I.E.</copyright-holder><copyright-holder xml:lang="ru">Черепнев Г.В., Слабнов Ю.Д., Зимакова И.Е.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://kazanmedjournal.ru/kazanmedj/article/view/64594">https://kazanmedjournal.ru/kazanmedj/article/view/64594</self-uri><abstract xml:lang="en"><p>The relevance of pharmacological correction of immunological reactivity is obvious: many socially significant diseases are accompanied by an imbalance in immune homeostasis. In the past few years, a number of reviews on the classification and mechanisms of action of immunotropic drugs approved for clinical use in the Russian Federation have been published in the domestic press.</p></abstract><trans-abstract xml:lang="ru"><p>Актуальность фармакологической коррекции иммунологической реактивности очевидна: многие социально значимые заболевания сопровождаются дисбалансом иммунного гомеостаза. В последние несколько лет в отечественной печати опубликован ряд обзоров по классификации и механизмам действия иммунотропных лекарственных средств, разрешенных к клиническому применению в Российской Федерации.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Kazan Medical archive</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>Казанский медицинский архив</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Axys Pharmaceuticals Announces Final Results of Lead Asthma Drug, APC-366, at American Lung Association/American Thoracic Society Meeting // www. axyspharm. com/asthma. html.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Biotechnology Therapeutic medicines and vaccines under development // Genet Eng News. — 1996.- Vol. 16,- P. 29 —34.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Epigenesis Pharmaceuticals, Inc awarded $100,000 SBIR grant to research novel asthma therapy // www. tkcom. com/releases/epi102197.htm.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Glaser V. // Genet Eng News. — 1998. — VoL18. — P. 1.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Idec primatized anti-CD4 antibody demonstrates clinival activity in severe asthma // Biotech News USA. — 1997.-Vol. 5. — P. 4.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Kraneveld A.D., Van Ank I., Van Der Linde H.J. et al. // J. Allergy Clin Immunol. - 1997. — Vol. 100. — P. 242 - 250.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Meng, Y.G., Sing N, Wong W.L. // Mol Immunol. — 1996. — Vol. 33. — P. 635 — 642.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Texas Biotechnology announces initiation of phase I clinical trial for TBC 1269 to treat asthma // www. tbc. сот/press/PRO/2/97. HTM.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Yoshie O, Imai T., Nomiyama H. // J. Leukoc. Biol - 1997. — Vol. 62. — P. 634 — 644.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Хаитов P.M., Пинегин Б.В., Истамов Х.И. Экологическая иммунология. — М., 1995.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Хаитов Р.М., Пинегин Б.В. // Иммунология. — 1996. — №6. — С. 4 — 9. 5. Epigenesis Pharmaceuticals, Inc awarded $100,000 SBIR grant to research novel asthma therapy // www.tkcom.com/ releases/epi102197.htm.</mixed-citation></ref></ref-list></back></article>
